ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

WuXi delists its small-molecule subsidiary STA

by Jean-François Tremblay, special to C&EN
March 15, 2019 | APPEARED IN VOLUME 97, ISSUE 11

 

The drug services firm WuXi AppTec will delist its small-molecule contract manufacturing subsidiary Shanghai SynTheAll (STA) from a Chinese stock exchange where it has traded since 2015. Delisting will save administrative expenses and allow STA to focus on its long-term development, WuXi says. STA operates process development and commercial production facilities in Shanghai’s Jinshan district and at a newer site in nearby Changzhou. In April, WuXi announced that STA will build a new facility in Jinshan large enough to accommodate 500 scientists.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment